PAPPA2
PAPPA2 (Pappalysin-2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.
Overview
Metalloproteinase which specifically cleaves insulin-like growth factor binding protein (IGFBP)-5 at the '163-Ser-|-Lys-164' bond. Shows limited proteolysis toward IGFBP-3.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Pembrolizumab.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PAPPA2 (Pappalysin-2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.
- 1 · What it is
PAPPA2 (Pappalysin-2) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.
- 2 · What goes wrong in cancer
Metalloproteinase which specifically cleaves insulin-like growth factor binding protein (IGFBP)-5 at the '163-Ser-|-Lys-164' bond. Shows limited proteolysis toward IGFBP-3.
- 3 · How drugs use it
No product in this corpus aims at PAPPA2 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:14615 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9BXP8 (protein name, function text, keywords and locations (REST API)); CIViC gene PAPPA2 (1 evidence items, 0 assertions, 1 variants; diseases: Lung Adenocarcinoma (GraphQL API, CC0))
Biology
Metalloproteinase which specifically cleaves insulin-like growth factor binding protein (IGFBP)-5 at the '163-Ser-|-Lys-164' bond. Shows limited proteolysis toward IGFBP-3. Location: Secreted (UniProt). Locus 1q25.2 (HGNC).
- Non-small-cell lung cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"PAPPA2" OR ABSTRACT:"PAPPA2" OR TITLE:"pappalysin 2" OR ABSTRACT:"pappalysin 2" OR TITLE:"Pappalysin-2" OR ABSTRACT:"Pappalysin-2" OR TITLE:"PAPPE" OR ABSTRACT:"PAPPE" OR TITLE:"PAPP-A2" OR ABSTRACT:"PAPP-A2" OR TITLE:"PLAC3" OR ABSTRACT:"PLAC3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PAPPA2, not a curated reading list.